According to MannKind Corporation, it remains committed to gaining approval for its Afrezza inhaled insulin despite continuing requests from the FDA for additional data. The company announced that it is restructuring in order to focus on the Afrezza approval, resulting in a layoff of 41% of its workforce. MannKind’s net loss for 2010 was more than $170 million. Read the company’s press release.
